Novartis' Kisqali Cuts Risk of Death by 19% in High-Risk Early Breast Cancer, Trial Shows
Fact checked by NewsPlainVerified by NewsPlain: confirmed by at least two named sources
Brief
Novartis' Kisqali lowered the risk of death by 19.1% after six…
Keep reading with NewsPlain Premium
Get the full brief, the full story, what's confirmed, what's still unclear, why it matters, and every source.
2 sources behind this story.